Investor Overview

Corporate Profile
Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$9.19
Change (%) Stock is Down 0.25 (2.65%)
Volume53,340
Data as of 05/17/13 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
05/14/13Jack Green Joins Verastem as Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 14, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the appointment of John “Jack” Green as Chief Financial Officer. Mr. Green was the former Chief Financial Officer of GTC Biotherapeutics and has held multiple senior finance roles in public and private biotechnology companies over the course of his career. ... 
Printer Friendly Version
05/09/13Verastem Reports First Quarter 2013 Financial and Corporate Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 9, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the quarter ended March 31, 2013, and also commented on certain corporate accomplishments and plans. “During the first quarter we made key strides in advancing our development programs targeting cancer stem cells,” said Christ... 
Printer Friendly Version
05/08/13Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 8, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences. The presentation details are as follows: UBS Global Healthcare Conference on May 22, 2013, at 8:30am ET at the Sheraton New York Hotel in New York, NY ... 
Printer Friendly Version
04/17/13Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 17, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences. The presentation details are as follows: 2013 BIO International Convention Business Forum on April 22, 2013, at 2:15pm CT in the Chicago Bears room of M... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.